ADMA Biologics Inc (NASDAQ:ADMA) – Research analysts at Zacks Investment Research cut their Q3 2018 earnings estimates for ADMA Biologics in a note issued to investors on Monday, October 15th. Zacks Investment Research analyst J. Vandermosten now expects that the biotechnology company will post earnings per share of ($0.31) for the quarter, down from their previous estimate of ($0.29). Zacks Investment Research also issued estimates for ADMA Biologics’ Q4 2018 earnings at ($0.30) EPS and FY2018 earnings at ($1.33) EPS.
ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Friday, August 10th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The business had revenue of $4.66 million during the quarter, compared to the consensus estimate of $5.35 million. ADMA Biologics had a negative net margin of 119.34% and a negative return on equity of 89.78%.
NASDAQ:ADMA opened at $5.53 on Thursday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 8.88 and a current ratio of 10.65. The company has a market capitalization of $248.89 million, a price-to-earnings ratio of -2.90 and a beta of 2.35. ADMA Biologics has a 12-month low of $2.01 and a 12-month high of $6.96.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Northern Trust Corp increased its stake in shares of ADMA Biologics by 618.2% during the second quarter. Northern Trust Corp now owns 209,313 shares of the biotechnology company’s stock worth $944,000 after purchasing an additional 180,170 shares during the period. 683 Capital Management LLC increased its stake in shares of ADMA Biologics by 9.9% during the second quarter. 683 Capital Management LLC now owns 885,000 shares of the biotechnology company’s stock worth $3,991,000 after purchasing an additional 80,000 shares during the period. Bank of New York Mellon Corp increased its stake in shares of ADMA Biologics by 188.0% during the second quarter. Bank of New York Mellon Corp now owns 54,828 shares of the biotechnology company’s stock worth $247,000 after purchasing an additional 35,791 shares during the period. Ardsley Advisory Partners bought a new position in shares of ADMA Biologics during the second quarter worth approximately $361,000. Finally, Stonepine Capital Management LLC bought a new position in shares of ADMA Biologics during the second quarter worth approximately $3,751,000. Institutional investors own 55.08% of the company’s stock.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Featured Story: Why investors pay attention to retained earnings
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.